Metastatic Castration-resistant Prostate Cancer Clinical Trials in Tacoma, Washington

5 studies are recruiting for metastatic castration-resistant prostate cancer in Tacoma, Washington right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

   The primary objective of this study is to compare overall survival (OS) in participants receiving xaluritamig plus abiraterone against investigator's choice (docetaxel, cabazitaxel, or abiraterone).

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Northwest Medical Specialties, PLLC, Tacoma, Washington

   Locations

   155 in total

   Run by

   Amgen

   See if you can join NCT07213674 on ClinicalTrials.gov

2. AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)

   The intention of the study is to demonstrate superiority of AZD2265 relative to standard of care treatments by assessment of radiographic progression-free survival (rPFS) and overall survival (OS) in participants with mCRPC.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Research Site, Tacoma, Washington

   Locations

   132 in total

   Run by

   AstraZeneca

   See if you can join NCT07611110 on ClinicalTrials.gov

3. A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

   This study will explore whether a combination of the investigational drug PF-06821497 and enzalutamide will work better than taking enzalutamide alone in participants with mCRPC who are ARSi or abiraterone naïve.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Northwest Medical Specialties, PLLC, Tacoma, Washington

   Locations

   236 in total

   Run by

   Pfizer

   See if you can join NCT06629779 on ClinicalTrials.gov

4. A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

   The purpose of this study is to evaluate the safety, efficacy, tolerability, and pharmacokinetics (PK) of FG-3246, a cluster of differentiation 46 (CD46) targeting antibody-drug conjugate (ADC), in the treatment of participants with mCRPC who have progressed following treatment with one prior secon…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Northwest Medical Specialties, PLLC - Tacoma, Tacoma, Washington

   Locations

   23 in total

   Run by

   Kyntra Bio

   See if you can join NCT06842498 on ClinicalTrials.gov

5. A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer

   Medicines that reduce the amount of testosterone in the body are commonly used to treat prostate cancer. PRL-02 depot is a potential treatment for men with advanced prostate cancer. It is given by an injection into the muscle. Men with advanced prostate cancer can take part in this study. Their can…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Northwest Medical Specialties, Tacoma, Washington

   Locations

   25 in total

   Run by

   Astellas Pharma Global Development, Inc.

   See if you can join NCT04729114 on ClinicalTrials.gov